JO3092B1 - مركب لتحفيز مسيطر عليه للمبيض - Google Patents

مركب لتحفيز مسيطر عليه للمبيض

Info

Publication number
JO3092B1
JO3092B1 JOP/2012/0197A JOP20120197A JO3092B1 JO 3092 B1 JO3092 B1 JO 3092B1 JO P20120197 A JOP20120197 A JO P20120197A JO 3092 B1 JO3092 B1 JO 3092B1
Authority
JO
Jordan
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
stimulation
Prior art date
Application number
JOP/2012/0197A
Other languages
English (en)
Inventor
Arce Joan-Carles
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3092(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3092B1 publication Critical patent/JO3092B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بمستحضرات تحتوي على FSH ، مثل FSH معاود الارتباط، للاستخدام في علاج العقم.
JOP/2012/0197A 2011-08-08 2012-07-18 مركب لتحفيز مسيطر عليه للمبيض JO3092B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11176803 2011-08-08

Publications (1)

Publication Number Publication Date
JO3092B1 true JO3092B1 (ar) 2017-03-15

Family

ID=46785372

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0197A JO3092B1 (ar) 2011-08-08 2012-07-18 مركب لتحفيز مسيطر عليه للمبيض

Country Status (31)

Country Link
US (4) US9694052B2 (ar)
EP (9) EP3566712B1 (ar)
JP (5) JP6161609B2 (ar)
KR (7) KR20200121918A (ar)
CN (2) CN107281470A (ar)
AR (1) AR087476A1 (ar)
AU (3) AU2012293647B2 (ar)
BR (2) BR122020001644B1 (ar)
CA (1) CA2844282A1 (ar)
CY (1) CY1117214T1 (ar)
DK (8) DK3646881T3 (ar)
ES (7) ES2704878T3 (ar)
FI (1) FI3756681T3 (ar)
HK (2) HK1204923A1 (ar)
HR (7) HRP20230607T1 (ar)
HU (7) HUE041769T2 (ar)
IL (2) IL300380A (ar)
JO (1) JO3092B1 (ar)
LT (7) LT2821080T (ar)
MX (2) MX348981B (ar)
PL (7) PL3395357T3 (ar)
PT (6) PT3646881T (ar)
RS (7) RS64328B1 (ar)
RU (2) RU2739037C3 (ar)
SA (1) SA112330762B1 (ar)
SI (7) SI3646881T1 (ar)
SM (1) SMT201600038B (ar)
TR (2) TR201911269T4 (ar)
TW (2) TWI657822B (ar)
WO (1) WO2013020996A1 (ar)
ZA (2) ZA201400952B (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
DK3662925T3 (da) * 2015-04-17 2021-06-28 Ferring Bv Sammensætning, der omfatter fsh, til behandling af infertilitet
EP3628675A1 (en) 2015-06-26 2020-04-01 Ferring B.V. Methods of purification and/or viral inactivation
KR20180052128A (ko) * 2015-09-17 2018-05-17 글리코토페 게엠베하 증가된 안정성을 갖는 포유동물 난포-자극 호르몬 조성물
AU2017336338B2 (en) * 2016-09-30 2022-11-10 Myovant Sciences Gmbh Methods of treating female infertility
AU2018326556A1 (en) * 2017-09-01 2020-03-05 Ferring B.V. Composition for controlled ovarian stimulation
CN112088011A (zh) 2018-04-30 2020-12-15 辉凌公司 用于受控的卵巢刺激的组合物
TW202027780A (zh) 2018-10-17 2020-08-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US11576920B2 (en) 2019-03-18 2023-02-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN110841060A (zh) * 2019-11-21 2020-02-28 上海交通大学 Choriogonadotropin alfa在治疗多囊卵巢综合征中的应用
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
EP1074265A1 (en) * 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
IL161235A0 (en) * 2001-10-22 2004-09-27 Applied Research Systems Fsh composition, its preparation and use
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US8501719B2 (en) * 2005-11-08 2013-08-06 American Infertility Of New York Androgen treatment in females
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
SI2621517T2 (sl) * 2010-09-29 2023-11-30 Ferring B.V. Sestavek za uporabo pri zdravljenju neplodnosti
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
PL2741763T3 (pl) 2016-07-29
PL3646881T3 (pl) 2021-11-02
TW201309322A (zh) 2013-03-01
PT3646881T (pt) 2021-06-02
US20140329748A1 (en) 2014-11-06
CY1117214T1 (el) 2017-04-05
EP3395357B1 (en) 2019-05-15
TWI657822B (zh) 2019-05-01
JP2014522871A (ja) 2014-09-08
LT3646881T (lt) 2021-05-25
KR20210143934A (ko) 2021-11-29
AU2012293647A1 (en) 2014-02-27
SMT201600038B (it) 2016-02-25
MX348981B (es) 2017-07-06
KR102499969B1 (ko) 2023-02-14
US20200345814A1 (en) 2020-11-05
PL3566712T3 (pl) 2021-07-12
HUE044610T2 (hu) 2019-11-28
RU2739037C3 (ru) 2021-09-08
HUE062640T2 (hu) 2023-11-28
JP6161609B2 (ja) 2017-07-12
KR102111514B1 (ko) 2020-05-18
US9694052B2 (en) 2017-07-04
EP3566712A1 (en) 2019-11-13
LT4005588T (lt) 2024-03-25
SI3195875T1 (sl) 2018-11-30
DK3195875T3 (en) 2018-11-12
KR102353144B1 (ko) 2022-01-18
US20180028620A1 (en) 2018-02-01
TR201900071T4 (tr) 2019-01-21
EP3756681A1 (en) 2020-12-30
AU2016273925B2 (en) 2018-03-15
KR20230024442A (ko) 2023-02-20
HUE027674T2 (en) 2016-11-28
KR20140054191A (ko) 2014-05-08
ES2692774T3 (es) 2018-12-05
ES2742163T3 (es) 2020-02-13
EP4306174A2 (en) 2024-01-17
HRP20181639T1 (hr) 2018-12-14
NZ620369A (en) 2015-12-24
HK1204923A1 (en) 2015-12-11
DK3395357T3 (da) 2019-08-19
SI3756681T1 (sl) 2023-08-31
IL230696B2 (en) 2023-07-01
HUE041769T2 (hu) 2019-05-28
CA2844282A1 (en) 2013-02-14
ES2562648T3 (es) 2016-03-07
DK4005588T3 (da) 2024-04-29
AU2018203222A1 (en) 2018-05-24
EP3756681B1 (en) 2023-05-03
KR20200121918A (ko) 2020-10-26
BR122020001644B1 (pt) 2022-08-02
RU2014102924A (ru) 2015-09-20
DK3646881T3 (da) 2021-07-26
MX2014001489A (es) 2014-04-25
PT4005588T (pt) 2024-04-24
US11291708B2 (en) 2022-04-05
SA112330762B1 (ar) 2015-10-08
EP3566712B1 (en) 2021-01-27
RS61672B1 (sr) 2021-04-29
RU2739037C2 (ru) 2020-12-21
HUE054312T2 (hu) 2021-08-30
EP3646881B1 (en) 2021-04-28
IL230696B1 (en) 2023-03-01
HRP20190023T1 (hr) 2019-02-22
HRP20210722T1 (hr) 2021-06-11
PT3195875T (pt) 2018-10-31
RU2613324C2 (ru) 2017-03-15
LT3566712T (lt) 2021-03-10
RS64328B1 (sr) 2023-08-31
HUE040058T2 (hu) 2019-02-28
PL3756681T3 (pl) 2023-08-21
RS54561B1 (en) 2016-06-30
PL2821080T3 (pl) 2019-04-30
RU2017106756A3 (ar) 2020-07-09
PL3195875T3 (pl) 2019-01-31
JP6500050B2 (ja) 2019-04-10
RS58198B1 (sr) 2019-03-29
JP7309660B2 (ja) 2023-07-18
HRP20160145T1 (hr) 2016-04-08
JP6718951B2 (ja) 2020-07-08
AU2012293647B2 (en) 2016-10-06
EP2741763B1 (en) 2015-11-18
JP2023134561A (ja) 2023-09-27
RU2613324C3 (ru) 2021-06-09
LT3756681T (lt) 2023-07-25
HRP20230607T1 (hr) 2023-09-29
RS59107B1 (sr) 2019-09-30
AR087476A1 (es) 2014-03-26
RS57897B1 (sr) 2019-01-31
RS61843B1 (sr) 2021-06-30
DK2741763T3 (da) 2016-02-15
LT3195875T (lt) 2018-11-12
LT2821080T (lt) 2019-01-10
US20220370567A1 (en) 2022-11-24
CN103732243A (zh) 2014-04-16
JP2020147600A (ja) 2020-09-17
ES2884947T3 (es) 2021-12-13
EP4005588B1 (en) 2024-02-07
EP3195875B1 (en) 2018-07-25
IL230696A0 (en) 2014-03-31
WO2013020996A1 (en) 2013-02-14
EP3395357A1 (en) 2018-10-31
RU2017106756A (ru) 2019-01-23
KR20210099162A (ko) 2021-08-11
PT3395357T (pt) 2019-08-27
EP2821080A1 (en) 2015-01-07
PT3756681T (pt) 2023-07-25
EP3646881A1 (en) 2020-05-06
KR102014469B1 (ko) 2019-08-26
CN107281470A (zh) 2017-10-24
EP4306174A3 (en) 2024-04-10
ES2950911T3 (es) 2023-10-16
JP2017141253A (ja) 2017-08-17
EP2741763A1 (en) 2014-06-18
EP2821080B1 (en) 2018-10-10
DK3566712T3 (da) 2021-04-19
ES2871405T3 (es) 2021-10-28
HRP20191437T1 (hr) 2019-11-15
DK3756681T3 (da) 2023-07-31
JP2019077693A (ja) 2019-05-23
HK1198005A1 (zh) 2015-03-06
PL3395357T3 (pl) 2019-11-29
ES2704878T3 (es) 2019-03-20
KR20190100449A (ko) 2019-08-28
ZA201506382B (en) 2017-01-25
MX2020010991A (es) 2020-11-09
EP3195875A1 (en) 2017-07-26
BR112014002884A2 (pt) 2017-02-21
KR20190140098A (ko) 2019-12-18
IL300380A (en) 2023-04-01
AU2018203222B2 (en) 2020-03-12
FI3756681T3 (fi) 2023-07-28
DK2821080T3 (en) 2019-01-28
AU2016273925A1 (en) 2017-01-12
SI3395357T1 (sl) 2019-09-30
US10624953B2 (en) 2020-04-21
ZA201400952B (en) 2022-03-30
TWI555530B (zh) 2016-11-01
SI3646881T1 (sl) 2021-08-31
LT3395357T (lt) 2019-08-26
SI2741763T1 (sl) 2016-02-29
HUE053716T2 (hu) 2021-07-28
SI2821080T1 (sl) 2019-01-31
TW201716082A (zh) 2017-05-16
PT2821080T (pt) 2018-12-17
TR201911269T4 (tr) 2019-08-21
HRP20210277T1 (hr) 2021-04-02
SI3566712T1 (sl) 2021-04-30
EP4005588A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2020010991A (es) Composicion para la estimulacion ovarica controlada.
MX2021002900A (es) Composicion con complejos de nanoparticulas/anticuerpos de paclitaxel unidos a albumina para usarse al tratar linfoma.
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ707086A (en) Anti-cd40 antibodies and methods of use
UA116981C2 (uk) Сполуки для лікування спінальної м'язової атрофії
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
MX2017002852A (es) Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
MX354988B (es) Formulaciones de anticuerpo y metodos.
MX360774B (es) Antagonistas de progesterona.
MX2019003619A (es) Formulaciones de bromocriptina.
PH12015501088A1 (en) Dimeric compounds
MX365403B (es) Peptidos y metodos para usarlos.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
AU2014249346A8 (en) High purity ovarian cancer stem cells for active autologous immune therapy
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
AU2012240388A8 (en) Treatment regimens
MX356102B (es) Compuestos y métodos para tratar leucemia.
MX2019006783A (es) Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirim idin-2-ona.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes